Replimune Group, Inc. (REPL) announced positive top-line results from the primary analysis of the IGNYTE study on lead pipeline candidate RP1, in combination with Bristol Myers’ (BMY) blockbuster immuno- oncology drug Opdivo (nivolumab), in patients with anti-PD1 failed melanoma. The analysis was conducted by an independent central review. RP1 is based on a proprietary strain of herpes simplex virus, engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF, intended to maximize tumo ...